Male Fertility Gene Atlas

CRU Male Germ Cells

About Publications Search Walk Through

Table S2: Comparison of minor allele frequencies (MAFs) at 191 SNPs of 42 genes between 190 infertile patients and 190 fertile males (1st round of initial screening)

OKADA, Hiroyuki, et al. Genome-wide expression of azoospermia testes demonstrates a specific profile and implicates ART3 in genetic susceptibility. PLoS genetics, 2008, 4. Jg., Nr. 2, S. e26.

Publication: https://doi.org/10.1371/journal.pgen.0040026

Description

Disclaimer

The publication Genome-Wide Expression of Azoospermia Testes Demonstrates a Specific Profile and Implicates ART3 in Genetic Susceptibility by Hiroyuki Okada and Atsushi Tajima and Kazuyoshi Shichiri and Atsushi Tanaka and Kenichi Tanaka and Ituro Inoue is published under an open access no derivatives license: : https://creativecommons.org/. Open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Curation by the MFGA team

Pie chart of selected column

Table

ARTIFACTID CHR GENE Localization Variation MafCase MafControl SequencePositiona
rs2146162 (6q25.3) ACAT2 5-upstream G/A 39.1% 35.8% -1984
rs9364535 (6q25.3) ACAT2 intron4 A/T 39.0% 35.6% 7532
rs2273828 (6q25.3) ACAT2 3-downstream A/G 19.5% 19.7% 23963
rs9995300 (4q21.1) ART3 5-upstream A/G 41.3% 36.7% -2520
rs17001357 (4q21.1) ART3 intron3 C/T 40.5% 42.8% 12048
rs11097230 (4q21.1) ART3 intron3 A/G 34.0% 36.8% 19801
rs6836703 (4q21.1) ART3 intron11 G/A 42.9% 36.6% 34283
rs1128864 (4q21.1) ART3 exon12-non-synonymous T/C 39.5% 36.1% 37726
rs6840007 (4q21.1) ART3 3-downstream A/T 34.7% 31.9% 43329
rs13415981 (2q14) BUB1 5-upstream A/G 6.7% 7.3% -3947
rs11903773 (2q14) BUB1 intron6 C/T 7.2% 6.7% 9926
rs7609252 (2q14) BUB1 intron9 A/G 6.8% 7.6% 16200
rs7581640 (2q14) BUB1 intron19 T/C 6.0% 5.4% 34693
rs13398617 (2q14) BUB1 intron24 T/C 6.9% 7.4% 37155
rs13419537 (2q14) BUB1 3-downstream C/T 6.8% 8.0% 43371
rs7819740 (8p21.2) CDCA2 5-upstream G/T 33.9% 35.2% -4478
rs3812422 (8p21.2) CDCA2 5’-UTR A/C 31.8% 32.5% 149
rs4872315 (8p21.2) CDCA2 intron7 T/G 33.4% 34.4% 16088
rs11135869 (8p21.2) CDCA2 intron7 G/A 33.4% 34.3% 18842
rs2271104 (8p21.2) CDCA2 intron11 C/T 33.4% 33.9% 27124
rs7826705 (8p21.2) CDCA2 intron13 T/A 30.1% 34.1% 36321
rs4872318 (8p21.2) CDCA2 exon15-non-synonymous G/A 16.8% 16.2% 47819
rs7943007 (11q12.1) CDCA5 5-upstream C/G 13.0% 13.4% -5574
rs489489 (11q12.1) CDCA5 3’-UTR C/A 13.2% 13.6% 6086
rs565211 (16q24.3) CDT1 5-upstream C/T 25.1% 29.2% -1935
rs475667 (16q24.3) CDT1 exon2-synonymous T/C 19.6% 19.5% 780
rs480727 (16q24.3) CDT1 exon3-non-synonymous A/G 24.2% 26.8% 2042
rs8191478 (16q24.3) CDT1 3-downstream C/T 43.3% 41.4% 7242
rs9633172 (Xq26.3) CT45-2 3-downstream A/G 11.6% 8.2% 11971
rs13064112 (3p24.3) DAZL 5-upstream A/G 29.7% 29.5% -5891
rs4234538 (3p24.3) DAZL 5-upstream C/G 23.4% 28.2% -542
rs11710967 (3p24.3) DAZL exon2-synonymous G/A 6.8% 6.5% 6931
rs3773826 (3p24.3) DAZL intron9 G/A 10.5% 11.1% 12693
rs10510452 (3p24.3) DAZL 3-downstream A/G 15.6% 15.8% 21958
rs16884506 (5q11.2) DDX4 5-upstream A/G 31.2% 27.7% -6616
rs3761772 (5q11.2) DDX4 intron1 A/G 31.8% 30.0% 235
rs17699426 (5q11.2) DDX4 intron1 A/G 12.4% 13.5% 4634
rs12653775 (5q11.2) DDX4 intron2 C/T 43.8% 43.3% 12368
rs4865627 (5q11.2) DDX4 intron2 C/G 48.3% 43.5% 17485
rs3761776 (5q11.2) DDX4 intron3 C/A 45.3% 42.4% 25139
rs12652234 (5q11.2) DDX4 intron5 C/G 43.7% 39.1% 29062
rs7378817 (5q11.2) DDX4 intron6 T/C 28.9% 27.3% 36492
rs3789195 (5q11.2) DDX4 intron16 T/C 47.1% 43.7% 60193